Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 433

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

Open access
Dieci, Maria Vittoria, Radosevic-Robin, Nina, Fineberg, Susan, van den Eynden, Gert, Ternes, Nils, Penault-Llorca, Frederique, Pruneri, Giancarlo, D’Alfonso, Timothy M., Demaria, Sandra, Castaneda, Carlos, Sanchez, Joselyn, Badve, Sunil, Michiels, Stefan, Bossuyt, Veerle, Rojo, Federico, Singh, Baljit, Nielsen, Torsten, Viale, Giuseppe, Kim, Seong-Rim, Hewitt, Stephen, Wienert, Stephan, Loibl, Sybille, Rimm, David, Symmans, Fraser, Denkert, Carsten, Adams, Sylvia, Loi, Sherene, Salgado, Roberto·2018·Seminars in Cancer Biology

Abstract

Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2017.10.003

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 433

Metadata

Authors
Dieci, M. V., Radosevic-Robin, N., Fineberg, S., van den Eynden, G., Ternes, N., Penault-Llorca, F., Pruneri, G., D’Alfonso, T. M., Demaria, S., Castaneda, C., Sanchez, J., Badve, S., Michiels, S., Bossuyt, V., Rojo, F., Singh, B., Nielsen, T., Viale, G., Kim, S.-R., Hewitt, S., Wienert, S., Loibl, S., Rimm, D., Symmans, F., Denkert, C., Adams, S., Loi, S., & Salgado, R.
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2018-10
Volume
52
Issue
Pt 2
Pages
16-25
ISSN
1044-579X (ISSN-L)
OpenAlex
W2762153201
Cited by
433
References
41
FWCI
10.56
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. https://app.cochat.ai/papers/10.1016/j.semcancer.2017.10.003
The paper
Dieci, M. V., Radosevic-Robin, N., Fineberg, S., van den Eynden, G., Ternes, N., Penault-Llorca, F., Pruneri, G., D’Alfonso, T. M., Demaria, S., Castaneda, C., Sanchez, J., Badve, S., Michiels, S., Bossuyt, V., Rojo, F., Singh, B., Nielsen, T., Viale, G., Kim, S.-R., . . . Salgado, R. (2018). Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2017.10.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.